Evidence map›Paper›PMID 41533305›Full record

ArticleCNS drugs2026

Correction: Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia.

John M Kane, Orna Tohami, Kelli R Franzenburg, Mark Suett, Nir Sharon, Avia Merenlender-Wagner, Roy Eshet, Eran Harary, Christoph U Correll

Abstract readPublished Erratum
In one paragraph

Article in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

John M KaneDepartment of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA. jkane2@northwell.edu.ORCID http://orcid.org/0000-0002-2628-9442
Orna TohamiGlobal Innovative Medicines, Research and Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.
Kelli R FranzenburgGlobal Medical Affairs, Teva Pharmaceutical Industries, West Chester, PA, USA.
Mark SuettGlobal Medical Affairs, Teva UK Limited, Harlow, UK.
Nir SharonGlobal Innovative Medicines, Research and Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.
Avia Merenlender-WagnerGlobal Innovative Medicines, Research and Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.
Roy EshetGlobal Innovative Medicines, Research and Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.
Eran HararyGlobal Innovative Medicines, Research and Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.
Christoph U CorrellDepartment of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41533305
PMCPMC12855310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.